Hope S. Rugo, MD
Professor of Medicine and Winterhof Family Professor of Breast OncologyUniversity of California San Francisco Comprehensive Cancer Center
San Francisco, CA
Authored Items
Video Library
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
Video Library
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study.
Sami Diab, MD, Hope S. Rugo, MD, Lida A. Mina, MD, Shannon Puhalla, MD, Reshma Mahtani, DO, N. Lynn Henry, MD, PhD, Neelima Denduluri, MD, Denise Yardley, MD, Yao Wang, MD, Lillian Shahied Arruda, PhD, Iulia C. Tudor, PhD, Eric Gauthier, PharmD, PhD, Akos Czibere, MD, PhD, Jennifer K. Litton, MD, Sara A. Hurvitz, MD
November 2019 Vol 10, No 11
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer.
Last modified: January 31, 2024